• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

9.790 +0.140 (+1.45%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 375,451
Open 9.690
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 9.650
Today's Range 9.480 - 10.00
52wk Range 9.150 - 13.14
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
October 29, 2024
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
Via The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga

Performance

YTD
-17.24%
-17.24%
1 Month
-2.97%
-2.97%
3 Month
-19.56%
-19.56%
6 Month
+0.41%
+0.41%
1 Year
-16.15%
-16.15%

More News

Read More
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via Investor's Business Daily
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
August 05, 2024
Via Benzinga
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
Via Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
December 31, 2023
Via Talk Markets
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
Via Benzinga
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
October 22, 2023
Via Investor's Business Daily
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
October 05, 2023
Via Benzinga
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
September 24, 2023
Via The Motley Fool
Why Is Seagen Stock Trading Higher Today?
September 22, 2023
Via Benzinga
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
September 22, 2023
Via Investor's Business Daily
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
September 20, 2023
Via Benzinga
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Via MarketBeat
Topics Economy
Exposures Interest Rates
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
August 07, 2023
Via Investor's Business Daily
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
July 07, 2023
Via Benzinga
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023
Via Talk Markets
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
June 08, 2023
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Via Investor's Business Daily
Why Shares of Annexon Are Plummeting Thursday
May 25, 2023
Via The Motley Fool
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
May 15, 2023
Via Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
May 15, 2023
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
May 01, 2023
Via The Motley Fool
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
May 01, 2023
Via Benzinga
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
May 01, 2023
Via Investor's Business Daily
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap